| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K48477130 | CTRPv2 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |
| mRNA | BRD-K26531177 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.002 | 0.9 |
| mRNA | Cerulenin | CTRPv2 | pan-cancer | AAC | 0.0022 | 0.9 |
| mRNA | BRD-K55473186 | CTRPv2 | pan-cancer | AAC | 0.0031 | 0.9 |
| mRNA | ML203 | CTRPv2 | pan-cancer | AAC | -0.0025 | 0.9 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | 0.002 | 1 |
| mRNA | Gemcitabine | CTRPv2 | pan-cancer | AAC | 0.002 | 1 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.0027 | 1 |